Arvest Bank Trust Division cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 205,296 shares of the biopharmaceutical company’s stock after selling 5,543 shares during the period. Arvest Bank Trust Division’s holdings in Gilead Sciences were worth $13,340,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 0.7% in the second quarter. Vanguard Group Inc. now owns 102,062,449 shares of the biopharmaceutical company’s stock valued at $6,895,339,000 after acquiring an additional 715,569 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Gilead Sciences by 17.5% in the second quarter. Invesco Ltd. now owns 22,975,310 shares of the biopharmaceutical company’s stock valued at $1,552,213,000 after acquiring an additional 3,418,193 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Gilead Sciences by 0.8% in the second quarter. Price T Rowe Associates Inc. MD now owns 12,109,533 shares of the biopharmaceutical company’s stock valued at $818,120,000 after acquiring an additional 90,251 shares in the last quarter. Parnassus Investments CA grew its holdings in shares of Gilead Sciences by 13.3% in the third quarter. Parnassus Investments CA now owns 10,133,261 shares of the biopharmaceutical company’s stock valued at $642,246,000 after acquiring an additional 1,187,424 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its holdings in shares of Gilead Sciences by 1,208.1% in the second quarter. Nuveen Asset Management LLC now owns 9,847,359 shares of the biopharmaceutical company’s stock valued at $665,288,000 after acquiring an additional 9,094,586 shares in the last quarter. 79.28% of the stock is owned by institutional investors.

Shares of GILD stock traded down $0.13 on Tuesday, reaching $64.18. The company’s stock had a trading volume of 596,769 shares, compared to its average volume of 6,825,823. The company has a quick ratio of 2.87, a current ratio of 2.96 and a debt-to-equity ratio of 1.11. Gilead Sciences, Inc. has a 12-month low of $60.89 and a 12-month high of $70.50. The company has a market capitalization of $81.22 billion, a P/E ratio of 10.44, a PEG ratio of 3.95 and a beta of 1.11. The stock’s 50 day simple moving average is $66.16 and its 200-day simple moving average is $65.28.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.74 by $0.01. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The company had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.61 billion. During the same quarter last year, the business posted $1.84 earnings per share. The firm’s revenue was up .1% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post 6.63 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a $0.63 dividend. The ex-dividend date was Thursday, December 12th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.93%. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

In related news, EVP Brett A. Pletcher sold 2,095 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $66.06, for a total value of $138,395.70. Following the sale, the executive vice president now owns 17,826 shares in the company, valued at $1,177,585.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Brett A. Pletcher sold 4,000 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $64.52, for a total value of $258,080.00. Following the completion of the sale, the executive vice president now owns 23,921 shares in the company, valued at approximately $1,543,382.92. The disclosure for this sale can be found here. Insiders sold 45,622 shares of company stock worth $2,986,438 in the last quarter. 0.20% of the stock is currently owned by company insiders.

GILD has been the subject of several research reports. Wells Fargo & Co set a $81.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Friday, October 25th. Robert W. Baird set a $76.00 price objective on Gilead Sciences and gave the company a “hold” rating in a report on Friday, October 25th. Guggenheim set a $86.00 price objective on Gilead Sciences and gave the company a “buy” rating in a report on Friday, October 25th. BidaskClub lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Tuesday, December 31st. Finally, SunTrust Banks initiated coverage on Gilead Sciences in a report on Tuesday, November 12th. They set a “hold” rating and a $70.00 price objective for the company. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $78.91.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: Neutral Rating

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.